Nora Singer, MD

Dr. Singer serves as the Medical Director of The MetroHealth System (MHS) Clinical Trials Unit and the Director of Hub Research Capacity for the MetroHealth site of the NIH funded CWRU Clinical Trials and Science Collaborative (CTSC). She also as the Director of Rheumatology at the MHS and Professor of Medicine and Pediatrics at the Case Western Reserve University (CWRU) School of Medicine.

She received her B.S. in Biology from Union College and her M.D. from Albany Medical College. She completed a combined residency in Internal Medicine and Pediatrics and fellowship in adult and pediatric rheumatology, all at the University of Michigan. Her clinical expertise is in adult and pediatric rheumatology with emphasis on autoimmune and inflammatory disease.

Dr. Singer’s interest focus on the novel treatments and immune dysregulation in rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE) and Sjogren’s syndrome. Her current investigator-initiated research program focuses on the use of mesenchymal stem cells to induce immunological tolerance/quiescence in RA and JIA. She has longstanding interest in the immune interactions between the T-cell protein CD6 and its known ligand (CD166) and novel ligand (CD318). Dr. Singer helped discover this novel ligand and is involved in studying that pathway to target immune diseases with unmet needs. Dr. Singer is also involved in sponsored research with an emphasis on clinical trials performed via the networks that study childhood rheumatic disease and lupus.

Dr. Singer is a fellow of the American College of Rheumatology and has served on a number of committees; she is a past Chair of the Committee on Publications and a current member of the ACR Division Director Special Committee.